CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that nine abstracts from its cystic fibrosis (CF) research program, which is aimed at discovering and developing medicines that target the underlying cause of CF, will be presented at the 25th
-Vertex hiring for 150 jobs across the company to support global growth; Company plans to add more than 500 jobs through 2015- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Science has ranked the company #1 in the magazine's annual list
- High viral cure rate achieved with a 24-week INCIVEK combination regimen - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK™ (telaprevir) tablets
-12-week data support initiation of Phase 2b study to evaluate longer treatment duration for VX-509- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a
- Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved INCIVEK™ (telaprevir) tablets for a broad group of
-Quarter highlighted by approval and launch of INCIVEK TM for hepatitis C and completion of VX-770 Phase 3 program in cystic fibrosis- -Continued progress in advancing new combinations of medicines for the future treatment of hepatitis C and cystic fibrosis- CAMBRIDGE, Mass.
-First data to show potential for viral cure in many patients with a 12-week combination regimen of multiple direct-acting antivirals- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from ZENITH, an ongoing Phase 2 study
-INCIVEK was recently approved by the FDA and is now available for people with the most common form of chronic hepatitis C who are new to treatment and those who were treated before but not cured- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced
-Vertex gains worldwide rights to two distinct nucleotide analogues, ALS-2200 and ALS-2158, that act on hepatitis C polymerase- -Collaboration provides multiple opportunities to develop new "all-oral" combination regimens- CAMBRIDGE, Mass. , & SOUTH SAN FRANCISCO, Calif.
- Complete data presented at ECFS showed improvements in lung function and reductions in sweat chloride observed at week two of treatment were sustained through 48 weeks -
<br><br>
- Vertex also announces that 48-week data from the ENVISION study of VX-770 among children ages 6 to 11 years are consistent with previously announced 24-week results -